Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

By
Eric Schlumpf
July 15, 2026
2 min

Retinal Physician

Overview

Stuart Therapeutics is developing a topical therapy for retinitis pigmentosa (RP) using a collagen mimetic peptide platform. Preclinical studies in nonhuman primates show retinal penetration.

Background

Retinitis pigmentosa is a group of inherited retinal diseases leading to progressive vision loss. Current treatment options are limited.

Data Highlights

Preclinical studies demonstrate topical drop penetration throughout the posterior retina, including the retinal extracellular matrix region.

Key Findings

Stuart Therapeutics is focusing on a collagen mimetic peptide platform for RP.
The therapy aims to provide neuroprotective effects and reduce inflammation.
Topical application is designed to improve the overall health of the posterior retina.
Preclinical data shows effective penetration of the therapy in nonhuman primates.
The program is in preclinical development stages.